CD19 and diffuse large B-cell lymphoma: A preclinical study confirmed the high expression of CD37 on tumor cells of DLBCL, FL, MCL, MZL and CLL, which demonstrated the remarkable efficacy of anti-CD37 CAR-T to both CD19 positive B-cell lymphoma cell line and CD19 negative cell line in vitro.